New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
07:47 EDTCAH, HLS, TSRO, ZIOP, EBS, JNJ, UHS, AUXL, HCA, PFE, WAGMizuho to hold a conference
USA Healthcare Corporate Access Day is being held in New York on May 6.
News For WAG;UHS;TSRO;PFE;JNJ;HLS;HCA;EBS;CAH;AUXL;ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 27, 2015
06:55 EDTPFEHospira sees merger closing on or about September 3
Hospira (HSP) said in a regulatory filing that on August 21, Hospira and Pfizer (PFE) received clearance from the U.S. FTC, relating to the pending merger of Hospira with Perkins Holding Company, a wholly-owned subsidiary of Pfizer. All required regulatory approvals have now been secured, though the merger remains conditioned upon the expiration of a post-clearance waiting period in one foreign jurisdiction. Hospira expects the merger to close on or about September 3.
August 26, 2015
08:04 EDTHCAHCA Holdings UnitedHealth weakness creates buying opportunity, says Oppenheimer
Subscribe for More Information
07:32 EDTPFEPfizer launches Phase 3 trial of targeted therapy for breast cancer patients
Subscribe for More Information
06:16 EDTPFEAlvogen to acquire product portfolio from Pfizer for US market
Subscribe for More Information
August 25, 2015
14:16 EDTPFEMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
13:01 EDTJNJJ&J unit to sell Splenda brand to Heartland Food, terms not disclosed
Subscribe for More Information
10:21 EDTCAHCardinal Health to acquire majority stake in naviHealth
Cardinal Health announced that it is acquiring a majority stake in naviHealth and expects the transaction to close later this week. Privately-held naviHealth partners with health plans, health systems and providers to manage the post-acute segment of the care continuum. naviHealth's principal investor, Welsh, Carson, Anderson & Stowe, along with management, will continue to have an ownership interest in the business. Cardinal Health said it is acquiring 71% of naviHealth for approximately $290M, with a goal of acquiring the entire business within four years, in accordance with a series of call/put rights during that period of time. Cardinal expects this acquisition to be neutral to its FY16 non-GAAP diluted earnings per share from continuing operations as it is a partial period, and slightly accretive to non-GAAP diluted earnings per share from continuing operations beginning in FY17, the first full year post close. "From a GAAP perspective, it is too early in the process to provide any specific guidance on the amortization of intangible assets. Once the fair value estimates are complete, we will provide additional details. Recall that our FY16 assumptions provided on our earnings call on July 30, 2015 only included those acquisitions that had been completed through June 30," the company stated in an FAQ document related to the deal.
09:26 EDTCAH, HLSRBC Capital to hold a bus tour
Healthcare Bus Tour travels throughout Nashville, TN to visit with various healthcare companies on August 25-26.
09:03 EDTJNJAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
06:18 EDTJNJSears names Lynn Pendergrass as Hardlines president
Subscribe for More Information
August 24, 2015
12:57 EDTPFEFTC requires Pfizer to sell rights to four products as condition of buying Hospira
Subscribe for More Information
08:16 EDTPFEBristol-Myers, Pfizer to present new data on Eliquis at ESC Congress 2015
Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) announced that 22 abstracts will be presented at the ESC Congress 2015, to be held August 29 to September 2 in London, United Kingdom. The new data reinforce the Alliance's commitment to the ongoing evaluation of Eliquis in both the nonvalvular atrial fibrillation and venous thromboembolism patient populations. In addition, data from the AEGEAN study evaluating adherence among NVAF patients further extends the Alliance's commitment to patient care.
08:01 EDTPFEPfizer receives clearance from FTC for Hospira acquisition
Subscribe for More Information
August 23, 2015
12:35 EDTPFEBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
09:01 EDTJNJLeerink medical devices analyst holds an analyst/industry conference call
Medical Device Analyst Newitter, along with MEDACorp Specialists Dorance Dillon and Terence Farrell, discuss the Centers for Medicare & Medicaid Services' recently proposed "Comprehensive Care For Joint Replacement Payment Model" and how this model might influence ortho pricing and hospital-vendor relationships on an Analyst/Industry conference call to be held on August 24 at 1 pm.
08:05 EDTZIOPZiopharm discloses that it entered into a R&D agreement with MD Anderson
Subscribe for More Information
08:01 EDTPFEPfizer says two Phase 3 Trumenba studies met primary endpoints
Subscribe for More Information
August 20, 2015
11:33 EDTJNJLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
11:24 EDTPFEPfizer says Ibrance application validated by EMA
Subscribe for More Information
05:48 EDTTSROMizuho keeps TESARO, Verastem, OncoMed as top biotech picks
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use